Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.50 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.48 |
| ▸ | SGK1 | O00141 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553898 | 0.84 | ABL1 (0.54) | CAMKK2ABL1MAP4K1DYRK1ACLK1 | |
| SCHEMBL22553950 | 0.83 | IKBKB (0.55) | NEK1 | |
| SCHEMBL22553808 | 0.83 | IKBKB (0.55) | NEK1 | |
| SCHEMBL30731031 | 0.82 | CDC7 (0.62) | CAMKK2MAP4K1NEK1DYRK1ADYRK1B | |
| SCHEMBL22553723 | 0.81 | MAP4K1 (0.52) | CAMKK2ABL1MAP4K1DYRK1ACLK1 | |
| SCHEMBL22553748 | 0.80 | CYP1A2 (0.43) | ABL1MAP4K1CYP3A4 | |
| SCHEMBL8941903 | 0.79 | SGK1 (0.77) | CAMKK2ABL1MAP4K1NEK1DYRK1A | |
| SCHEMBL858529 | 0.76 | CAMKK2 (0.67) | CAMKK2DYRK1ASGK1DYRK1BCDC7 | |
| SCHEMBL8320557 | 0.75 | MAPK8 (0.70) | CAMKK2ABL1MAP4K1DYRK1ACLK1 | |
| SCHEMBL22554218 | 0.74 | CYP3A4 (0.46) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | claimed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | CAMKK2 488/4885ABL1 235/4885MAP4K1 69/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | CAMKK2 488/4885ABL1 235/4885MAP4K1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.